Sector News

Kite and bluebird join forces with some cutting-edge cancer tech

June 22, 2015
Life sciences
Immuno-oncology innovator Kite Pharma is joining gene therapy luminary bluebird bio to craft new treatments for HPV-related cancers, combining two high-profile technologies in hopes of developing targeted therapies.
 
Under the deal, Kite will bring its expertise in T cell receptor, or TCR, treatments, which rely on rewiring the body’s immune cells to home in on cancers. And bluebird will provide its know-how in using harmless viruses to deliver corrective genes and its experience in gene editing. Combined, the partners hope to produce second-generation TCRs that use bluebird’s genetic engineering platform to better attack their target cancers, particularly those related to a particular strain of HPV, or human papillomavirus.
 
The companies aren’t disclosing financial details of the deal, saying only that they will share all R&D and commercial costs and split profits 50-50. Kite will lead the effort in the U.S., while bluebird will have the option to run things in Europe, and each company is eligible for co-promotion rights in the other’s territory.
 
Kite is largely known for its work on CAR-T therapies, a cousin technology to TCR that has shown excellent early promise against blood cancers. In CAR-T, the California biotech is in a race with Novartis and Juno Therapeutics, planning to enter pivotal trials this year with its leading contender.
 
But less often discussed is Kite’s TCR pipeline, which features 5 National Cancer Institute-partnered therapies in the early stages of development, and the company is pursuing both paths in tandem with the goal of churning out therapies for tumors liquid and solid.
 
As for bluebird, the biotech has made headlines around the world with its lead gene therapy, which has shown the potential to cure a rare blood disease. But the Cambridge, MA, company has long been working in CAR-T, as well, lending its technology to Celgene ($CELG) over the past few years in a wide-ranging blood cancer collaboration. Earlier this month, Celgene scaled back that partnership to cover just a single target, with bluebird regaining the rights to a handful of programs and maintaining some in-house CAR-T candidates.
 
Now, pairing off with Kite, bluebird is reaching into the world of TCR in an effort to “deliver game-changing T cell therapies to patients through great science and great capabilities,” CEO Nick Leschly said in a statement.
 
By Damian Garde
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend